Welcome to our dedicated page for Sonoma Pharmaceu news (Ticker: SNOA), a resource for investors and traders seeking the latest updates and insights on Sonoma Pharmaceu stock.
Sonoma Pharmaceuticals develops and commercializes stabilized hypochlorous acid products based on its Microcyn technology for wound care, dermatology, eye, oral and nasal care, podiatry, animal health and non-toxic disinfection. Company news commonly covers HOCl product launches, partner distribution arrangements, retail channel expansion, dermatology brand collaborations and product recognition for sensitive-skin applications.
Recurring updates also include operating and financial results, regulatory and quality initiatives, manufacturing and product-listing disclosures, international distribution activity, and board or senior leadership changes. Sonoma’s releases frequently connect its Microcyn-based formulations with consumer and professional healthcare uses, including burn relief, itch-burn-rash-pain relief, scar care and sensitive-skin dermatology products.
Sonoma Pharmaceuticals, a leader in hypochlorous acid products for healthcare, has announced CEO Amy Trombly and CFO Jerry Dvonch will present at two virtual conferences: the H.C. Wainwright Global Life Sciences Conference from March 9-10, 2021, and the Maxim Emerging Growth Conference from March 17-18, 2021. Both presentations will be available on demand. Investors interested in meetings with management can contact the respective conference coordinators. Sonoma's products address various health issues and are available in 54 countries.
Sonoma Pharmaceuticals (Nasdaq: SNOA) reported a 12% revenue increase to $4.94 million for Q3 FY2020, driven by sales growth in Latin America and Europe, despite a decline in U.S. revenue due to COVID-19. Operating expenses decreased by 31% to $2.13 million, primarily from headcount reductions and facility closures. The net loss from continuing operations improved to $626,000 compared to $1.21 million in Q3 FY2019. Over nine months, revenue rose 21% to $16.47 million, although gross margins decreased to 41%. Sonoma's cash reserves increased to $5.44 million, signifying improved liquidity.
Sonoma Pharmaceuticals (Nasdaq: SNOA) announces that its Dermodacyn® disinfectant has received import clearance as a medical device for Thailand. This product, which has shown effectiveness against SARS-CoV-2, is now available in pharmacies and online in Hong Kong and Thailand. Dermodacyn is designed for disinfecting areas that may harbor harmful bacteria and viruses, with safety for human use being a key feature. Sonoma's CEO stated plans for ongoing research and development to expand product offerings.
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) announced that CEO Amy Trombly and CFO Jerry Dvonch will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference from January 11-14, 2021. The presentation will be available on-demand starting at 6:00 AM ET on January 11. Registration for the presentation can be accessed here. The company specializes in stabilized hypochlorous acid products for various healthcare applications.
Sonoma Pharmaceuticals (Nasdaq: SNOA) has entered into a non-exclusive distribution agreement with Gabriel Science, LLC to market its Microcyn® Technology products in the dental sector, receiving its first order.
Endocyn®, a product in this line, is a biocompatible root canal irrigant shown to have lower cellular toxicity than traditional irrigants in a study by Louisiana State University. The partnership aims to enhance Sonoma's market presence in dental healthcare, promoting advanced treatment options for dental conditions.